Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
In Crohn’s disease and ulcerative colitis, inflammation is not limited to the digestive tract. Extraintestinal manifestations (EIMs), which affect up to 50% of patients, can substantially impair quality of life. EIMs may parallel luminal disease activity or have an independent course. They most comm...
| Publicado en: | Drugs Vol. 81; no. 2; pp. 333 - 348 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Feb2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |